Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam versus sevoflurane for postoperative delirium and early cognitive dysfunction in elderly surgical patients
ChiCTR2200064984Phase 4Not yet recruiting
- Sponsor
- Tai'an City Central Hospital
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of remimazolam and sevoflurane in postoperative delirium (POD) and post-operative cognitive decline (POCD) (3 arms), sponsored by Tai'an City Central Hospital. Primary endpoint: Incidence of postoperative delirium. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
remimazolamsevoflurane
03
Conditions
postoperative delirium (POD)post-operative cognitive decline (POCD)
Beyond the preview
Go deeper on ChiCTR2200064984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064984.